Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB Science AB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • English
  • French
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: News

You are here:
  1. Home
  2. Category "News"

Results of masitinib study in metastatic melanoma

2019By Alexis BERNARDAugust 2, 2019

02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.

AB Science Corporate Presentation

2019By Alexis BERNARDJuly 22, 2019

22/07/2019 – AB Science Corporate Presentation – July 2019  

Summary of the webconference held on July 8, 2019

2019By Alexis BERNARDJuly 9, 2019

09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019

July 8 2019 web conference presentation

2019By Alexis BERNARDJuly 8, 2019

08/07/2019 – AB Science web conference presentation

Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD

2019By Alexis BERNARDJuly 8, 2019

08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure

2019By Alexis BERNARDJuly 4, 2019

04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.

Results of interim analysis for masitinib in Alzheimer’s Disease

2019By Alexis BERNARDJune 26, 2019

26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

June 14 2019 web conference presentation

2019By Alexis BERNARDJune 14, 2019

14/06/2019 – AB Science web conference presentation

Positive IDMC recommendation following interim analysis in pancreatic cancer

2019By Alexis BERNARDJune 12, 2019

12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer

Upcoming news flow

2019By Alexis BERNARDJune 10, 2019

10/06/2019 – AB Science is providing the upcoming news flow of the Company

←1
2345678910
…111213141516→
AB Science
© AB Science – All right reserved
Go to Top